Literature DB >> 7481840

Induction of apoptosis by gemcitabine.

P Huang1, W Plunkett.   

Abstract

Inhibition of cellular DNA synthesis is the major action of gemcitabine. In cells, this drug is converted to its triphosphate (dFdCTP), which is incorporated into DNA and terminates DNA strand elongation. After incorporation of gemcitabine nucleotide into the DNA strand, one more deoxynucleotide is incorporated, and thereafter the DNA polymerases are unable to proceed ("masked chain termination"). Gemcitabine also inhibits DNA synthesis indirectly by decreasing cellular dNTP pools via inhibition of ribonucleotide reductase. Incubation of human leukemia cells (CEM) with gemcitabine leads to apoptotic cell death. Two types of DNA fragmentation were observed in the gemcitabine-treated cells: (1) large-sized double-stranded DNA fragments range from 5 kb to 500 kb with the majority of the fragments located at 50 kb, and (2) nucleosomal-sized DNA fragments. Both types of drug-induced DNA fragmentation were detected in exponentially growing cells and were much more prominent in cells synchronized at S phase. The gemcitabine-induced DNA fragmentation in either synchronized or nonsynchronized cells was inhibited by the DNA synthesis inhibitor, aphidicolin. Thus, incorporation of gemcitabine into DNA is essential to induce DNA fragmentation. The intracellular calcium chelator BAPTA-AM inhibited the drug-induced nucleosomal DNA fragmentation but did not prevent the large-sized DNA fragmentation, suggesting that the nucleosomal DNA fragmentation is a calcium-dependent event, whereas the large-sized DNA fragmentation is independent of calcium. Furthermore, BAPTA-AM did not prevent the morphologic appearance of apoptotic bodies in cells incubated with gemcitabine, indicating that degradation of DNA to nucleosomal fragments is not an essential element of the apoptotic process. Phorbol 12-myristate 13-acetate also inhibited drug-induced nucleosomal DNA fragmentation, but prevented neither large-sized DNA fragmentation nor formation of apoptotic bodies. In contrast, aphidicolin inhibited both types of DNA fragmentation and blocked the formation of apoptotic bodies in the presence of gemcitabine. These data suggest that the generation of large-sized DNA fragments caused by incorporated gemcitabine monophosphate in DNA is critical in gemcitabine-induced apoptosis, whereas nucleosomal DNA fragmentation is not a requirement in this cell death process.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7481840

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  35 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.

Authors:  Emmanuel I Papadopoulos; George M Yousef; Andreas Scorilas
Journal:  Tumour Biol       Date:  2015-04-02

Review 3.  Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.

Authors:  Sau Wai Hung; Hardik R Mody; Rajgopal Govindarajan
Journal:  Cancer Lett       Date:  2012-03-13       Impact factor: 8.679

4.  Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.

Authors:  Dharmika S P Lansakara-P; B Leticia Rodriguez; Zhengrong Cui
Journal:  Int J Pharm       Date:  2012-03-16       Impact factor: 5.875

Review 5.  Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

Authors:  Raphaël Maréchal; Anne Demols; Jean-Luc Van Laethem
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

6.  Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.

Authors:  Peter Schmid; Volker Heilmann; Carsten-Oliver Schulz; Annette Dieing; Silvia Lehenbauer-Dehm; Christian Jehn; Orhan Sezer; Kurt Possinger; Bernd Flath
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

7.  Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study.

Authors:  Peter Schmid; Bernd Flath; Konstantin Akrivakis; Volker Heilmann; Hans-Günther Mergenthaler; Orhan Sezer; Rolf Kreienberg; Kurt Possinger
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

8.  Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.

Authors:  Peter Schmid; Marcus Schweigert; Thomas Beinert; Bernd Flath; Orhan Sezer; Kurt Possinger
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

9.  Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice.

Authors:  Tai-Guo Liu; Ying Huang; Dan-Dan Cui; Xiao-Bing Huang; Shu-Hua Mao; Ling-Ling Ji; Hai-Bo Song; Cheng Yi
Journal:  BMC Cancer       Date:  2009-07-23       Impact factor: 4.430

10.  The role of apoptotic cell death in the radiosensitising effect of gemcitabine.

Authors:  B Pauwels; J B Vermorken; A Wouters; J Ides; S Van Laere; H A J Lambrechts; G G O Pattyn; K Vermeulen; P Meijnders; F Lardon
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.